Director: Professor Ian Wilkinson (University of Cambridge)
Co-directors (Industry Partners): Dr. Stephen Rennard (AstraZeneca), Dr. Danielle Gerlag (GSK), Dr. David Howe (MedImmune)
University of Cambridge Faculty: Dr. Joseph Cheriyan, Professor Duncan Jodrell, Dr. Menna Clatworthy, Dr. Carmel McEniery, Dr. Ferdia Gallagher, Dr. Kevin O’Shaughnessy, Dr. David Jayne, Dr. Frank Waldron-Lynch
Management of the EMI: Dr. Mellone Marchong (Office of Translational Research), Mrs. Elizabeth McIntyre, Mrs. Ann Enticknap (Clinical Academic Training Office)
The Experimental Medicine Training Initiative (EMI) is an exciting, strategic scheme, supported by the University of Cambridge in partnership with the Cambridge University Hospitals, NIHR Cambridge Biomedical Research Centre and Industry Partners AstraZeneca/MedImmune and GSK, designed to build capacity in Experimental Medicine (EM).
The development of new drugs and innovative therapies increasingly relies on EM studies in humans, such as obtaining early proof-of-concept, understanding (patho-) physiology, biomarker development/validation, and evaluating techniques for subject stratification. Currently there is a lack of individuals trained to design and deliver such studies, which is impacting on drug development. Academia and pharmaceutical R&D are keen to collaborate to address this translational research gap, and in doing so deliver high quality Experimental Medicine projects.
The Initiative is providing high quality training for highly motivated, bright and enthusiastic clinicians, and non-clinical scientists in the design and execution of Experimental Medicine studies, equipping them with the knowledge and skills to lead Experimental Medicine studies in the future. The initiative will also recruit experienced individuals to new, joint posts, created as part of the initiative, to support Experimental Medicine studies and training in Cambridge, and create opportunities for the exchange of individuals between partners through sabbaticals and secondments.
The Office of Translational Research (OTR) and the Clinical Academic Training Office (CATO) jointly manage EMI activities – agreements, funding, recruitment, training. CATO provide recruitment and training support. OTR provide research collaboration and agreement support.
For further information and detail on EMI go here
In addition to the hands on exposure to the design and conduct of EM studies and investigating the therapeutic potential of new drugs in collaboration with our industrial partners, students of Experimental Medicine can access training opportunities through the EMI Training Registration site , which is a portal for attendees to register membership, provide feedback and attain a certificate.
Go to EMI-training.org to register as a member and book a place on a training event.
Training events will include discussions, interactive sessions and small group work to facilitate learning and training in drug development activities, particularly pre-clinical phase 3 and licensing. Industry partners will deliver talks and lead on discussions.
Royal College of Physicians – all training events will be RCP CPD accredited for delegates to add to their portfolios.
Learning Objectives – are set for each training event for delegates to add to portfolios and Personal Development Plans.
Resources – learning resources, handouts and course materials may be provided as required.
Recruitment – Types of posts available
Information regarding PhD positions, Junior Medical Training and Clinical Lectureships can be found on this site under ‘recruitment’.
PhD Studentships & Clinical Research Associateships
These will be 3 year posts, with an additional 6-month taught component for those who have not completed the MPhil, which will equip students with the scientific and regulatory knowledge required to undertake Experimental Medicine studies in man.
Students will cover the following modules from the new MPhil in Clinical Science and specialist training in Clinical Pharmacology: Practical Aspects of Clinical Research; Basic Pharmacology; Pharmacokinetics; Toxicology; Clinical Drug Development; and Medical Statistics.
PhD projects will be developed jointly by industry and academic partners, and should include at least one Experimental Medicine study involving giving a drug/or challenge agent to human subjects. Other components may include mechanistic, laboratory-based analyses, and biomarker discovery/development/validation.
There is an option to spend up to a year based with the industrial partner, or other Departments within the University. All students will have joint University and industry partner supervisors, and a separate academic mentor.
Posts have two stages of application and approval:
- Application and interview by a panel of University and industry academics.
- The successful applicant will then apply to the University of Cambridge PhD course in Medicine and be subject to the graduate admissions process of the University of Cambridge.
Posts open to recruitment can be found via the recruitment pages
Details regarding Senior Experimental Medicine Investigators and Post-Doctoral Clinical Scientists Posts can be found on the EMIT website